Chemomab Therapeutics (NASDAQ:CMMB) Announces Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB) announced its quarterly earnings data on Wednesday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.23), Zacks reports.

Chemomab Therapeutics Stock Performance

CMMB stock traded up $0.01 during trading on Wednesday, reaching $1.92. The company had a trading volume of 2,063 shares, compared to its average volume of 89,670. The company has a market cap of $13.85 million, a price-to-earnings ratio of -0.87 and a beta of 0.65. Chemomab Therapeutics has a twelve month low of $1.35 and a twelve month high of $4.12. The firm has a 50-day simple moving average of $1.71 and a 200-day simple moving average of $1.71.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. XTX Topco Ltd acquired a new position in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned approximately 0.31% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $25.00.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.